Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients.

distant recurrence neoadjuvant chemotherapy pathologic complete response (pCR) peripheral blood counts platelet-to-lymphocyte ratio (PLR) triple negative breast cancer (TNBC) tumor-infiltrating lymphocytes (TILs)

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2021
Historique:
received: 09 03 2021
accepted: 29 06 2021
entrez: 9 8 2021
pubmed: 10 8 2021
medline: 10 8 2021
Statut: epublish

Résumé

Triple negative breast cancer (TNBC) is highly heterogeneous, but still most of the patients are treated by the anthracycline/taxane-based neoadjuvant therapy (NACT). Tumor-infiltrating lymphocytes (TILs) are a strong predictive and prognostic biomarker in TNBC, however are not always available. Peripheral blood counts, which reflect the systemic inflammatory/immune status, are easier to obtain than TILs. We investigated whether baseline white cell or platelet counts, as well as, Neutrophil-to-Lymphocyte Ratio (NLR) or Platelet-to-Lymphocyte Ratio (PLR) could replace baseline TILs as predictive or prognostic biomarkers in a series of TNBC treated by standard NACT. One hundred twenty patients uniformly treated by FEC/taxane NACT in a tertiary cancer care center were retrospectively analyzed. The presence of pathological complete response (pCR: ypT0/Tis, ypN0) or the presence of pCR and/small residual disease (ypT0/Tis/T1ab, ypN0) were considered as good responses in data analysis. Baseline/pre-NACT blood count, NLR, PLR and TILs were evaluated as predictors of response, distant recurrence rate and distant recurrence-free survival (DRFS). TILs ≥30% and ≥1.5% were best predictors of pCR and distant recurrence risk, respectively (p = 0.007, p = 0.012). However, in this cohort, pCR status was not significantly associated with recurrence. Only the ensemble of patients with pCR and small residual disease had lower recurrence risk and longer survival DRFS (p = 0.042, p = 0.024, respectively) than the rest of the cohort (larger residual disease). The only parameter which could predict the pCR/small residual disease status was PLR: patients with values lower than 133.25 had significantly higher chance of reaching that status after NACT (p = 0.045). However, no direct correlation could be established between baseline PLR and metastatic recurrence. No correlation either was found between TIL and individual blood counts, or between TILs and NLR or PLR. In this cohort, TILs retained their pCR predictive value; however PLR was a better predictor of the ensemble of responses which had good outcome in terms of less distant recurrences or longer DRFS (pCR or small residual disease). Thus, baseline PLR is worth further, prospective investigation together with baseline TILs, as it might indicate a good TNBC response to NACT when TILs are unavailable.

Identifiants

pubmed: 34367964
doi: 10.3389/fonc.2021.678315
pmc: PMC8331686
doi:

Types de publication

Journal Article

Langues

eng

Pagination

678315

Informations de copyright

Copyright © 2021 Lusho, Durando, Mouret-Reynier, Kossai, Lacrampe, Molnar, Penault-Llorca, Radosevic-Robin and Abrial.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Clin Cancer Res. 2018 Dec 1;24(23):5820-5829
pubmed: 30061361
Ann Oncol. 2014 Mar;25(3):611-618
pubmed: 24401929
PLoS One. 2018 Jul 26;13(7):e0200936
pubmed: 30048474
Breast Cancer Res Treat. 2019 Apr;174(2):443-452
pubmed: 30604000
Eur J Surg Oncol. 2019 Jun;45(6):963-968
pubmed: 30745134
J Surg Oncol. 2011 Oct;104(5):504-10
pubmed: 21618251
Asian Pac J Cancer Prev. 2014;15(6):2651-4
pubmed: 24761879
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Curr Oncol. 2018 Apr;25(2):e113-e119
pubmed: 29719435
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
BMC Cancer. 2018 Feb 3;18(1):129
pubmed: 29394917
J Gastrointest Oncol. 2016 Apr;7(2):189-95
pubmed: 27034785
Sci Rep. 2018 Jun 7;8(1):8703
pubmed: 29880896
Onco Targets Ther. 2020 Feb 14;13:1397-1412
pubmed: 32104003
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
Breast Cancer Res Treat. 2012 Apr;132(3):793-805
pubmed: 21562709
Front Oncol. 2018 Mar 21;8:78
pubmed: 29619344
Cancer Med. 2019 Aug;8(9):4135-4148
pubmed: 31197958
Cancer Manag Res. 2018 Oct 24;10:4891-4898
pubmed: 30425580
Medicine (Baltimore). 2020 Dec 11;99(50):e23418
pubmed: 33327268
Clin Breast Cancer. 2009 Feb;9(1):29-33
pubmed: 19299237
Ann Pathol. 1999 Sep;19(4):336-43
pubmed: 10544774
Am J Surg. 2009 Apr;197(4):466-72
pubmed: 18639229
BMC Cancer. 2020 Mar 4;20(1):179
pubmed: 32131780
Anticancer Res. 2018 Dec;38(12):6905-6910
pubmed: 30504408
Arch Pathol Lab Med. 2014 Feb;138(2):241-56
pubmed: 24099077
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818791500
pubmed: 30145940
Diagn Pathol. 2018 Aug 31;13(1):66
pubmed: 30170605
Hum Pathol. 2008 Aug;39(8):1221-8
pubmed: 18547616
Breast. 2019 Apr;44:33-38
pubmed: 30611095
PLoS One. 2018 Nov 14;13(11):e0207224
pubmed: 30427884
Anticancer Res. 2018 Apr;38(4):2311-2321
pubmed: 29599354
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
J Clin Oncol. 2019 Mar 1;37(7):559-569
pubmed: 30650045
Clin Breast Cancer. 2020 Aug;20(4):e403-e409
pubmed: 32201163
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
J BUON. 2015 Nov-Dec;20(6):1432-9
pubmed: 26854438
Clin Cancer Res. 2001 Oct;7(10):3025-30
pubmed: 11595690
Cancers (Basel). 2019 Jun 28;11(7):
pubmed: 31261762
J Clin Oncol. 2007 Oct 1;25(28):4414-22
pubmed: 17785706
Biomarkers. 2012 May;17(3):216-22
pubmed: 22424597
Cancers (Basel). 2020 Sep 18;12(9):
pubmed: 32962003
PLoS One. 2016 Jul 29;11(7):e0153459
pubmed: 27472762
Eur J Cancer. 2020 Sep;136:7-15
pubmed: 32622323
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
BMC Cancer. 2015 Mar 28;15:195
pubmed: 25884918
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-16
pubmed: 32315235
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Eur J Cancer. 2013 May;49(7):1673-82
pubmed: 23265706
Clin Cancer Res. 2017 Aug 1;23(15):4035-4045
pubmed: 28270498
Oncotarget. 2017 Nov 20;8(68):112712-112719
pubmed: 29348858
J Clin Oncol. 2017 Apr 1;35(10):1049-1060
pubmed: 28135148
Nat Rev Clin Oncol. 2016 Apr;13(4):228-41
pubmed: 26667975
Oncol Lett. 2019 Dec;18(6):6275-6283
pubmed: 31788105
Cancer Res Treat. 2019 Apr;51(2):649-663
pubmed: 30064200
Am J Hosp Pharm. 1990 Nov;47(11 Suppl 3):S11-5
pubmed: 2275476
Oncotarget. 2016 Jul 12;7(28):44288-44298
pubmed: 27329588
BMC Cancer. 2013 Jul 22;13:350
pubmed: 23876227
Ann Surg Oncol. 2016 Apr;23(4):1104-10
pubmed: 26511266
Med Oncol. 2013 Mar;30(1):388
pubmed: 23292831
Arch Pathol Lab Med. 2020 May;144(5):545-563
pubmed: 31928354

Auteurs

Sejdi Lusho (S)

Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.
Delegation for Clinical Research and Innovation, Centre Jean Perrin, Clermont-Ferrand, France.
Centre for Clinical Investigation, INSERM U501, Clermont-Ferrand, France.

Xavier Durando (X)

Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.
Delegation for Clinical Research and Innovation, Centre Jean Perrin, Clermont-Ferrand, France.
Centre for Clinical Investigation, INSERM U501, Clermont-Ferrand, France.
Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.

Marie-Ange Mouret-Reynier (MA)

Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.
Delegation for Clinical Research and Innovation, Centre Jean Perrin, Clermont-Ferrand, France.
Centre for Clinical Investigation, INSERM U501, Clermont-Ferrand, France.
Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.

Myriam Kossai (M)

Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.
Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France.

Nathalie Lacrampe (N)

Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.
Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France.

Ioana Molnar (I)

Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.
Delegation for Clinical Research and Innovation, Centre Jean Perrin, Clermont-Ferrand, France.
Centre for Clinical Investigation, INSERM U501, Clermont-Ferrand, France.

Frederique Penault-Llorca (F)

Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.

Nina Radosevic-Robin (N)

Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.
Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France.

Catherine Abrial (C)

Clermont Auvergne University, INSERM U1240 "Molecular Imaging and Theranostic Strategies", Centre Jean Perrin, Clermont-Ferrand, France.
Delegation for Clinical Research and Innovation, Centre Jean Perrin, Clermont-Ferrand, France.
Centre for Clinical Investigation, INSERM U501, Clermont-Ferrand, France.

Classifications MeSH